HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings

Climb Bio, Inc. (NASDAQ:CLYM) – Research analysts at HC Wainwright lowered their Q1 2026 EPS estimates for shares of Climb Bio in a report released on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.28) for the quarter, down from their previous estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Climb Bio’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.08) EPS and FY2027 earnings at ($1.18) EPS.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06).

CLYM has been the topic of several other reports. Raymond James Financial assumed coverage on Climb Bio in a research report on Tuesday. They issued a “strong-buy” rating on the stock. Wedbush began coverage on Climb Bio in a report on Thursday, March 5th. They set an “outperform” rating and a $12.00 target price on the stock. Robert W. Baird boosted their target price on Climb Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research note on Wednesday, January 21st. Finally, Piper Sandler assumed coverage on shares of Climb Bio in a research note on Friday, February 13th. They set an “overweight” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Climb Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.40.

Climb Bio Stock Performance

CLYM opened at $7.26 on Thursday. The company has a fifty day moving average price of $5.45 and a two-hundred day moving average price of $3.46. The firm has a market capitalization of $494.99 million, a PE ratio of -8.16 and a beta of -0.25. Climb Bio has a 52 week low of $1.05 and a 52 week high of $8.04.

Institutional Investors Weigh In On Climb Bio

Several large investors have recently modified their holdings of CLYM. Peapod Lane Capital LLC increased its stake in Climb Bio by 0.7% during the 4th quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock worth $2,264,000 after purchasing an additional 4,126 shares in the last quarter. XTX Topco Ltd lifted its stake in Climb Bio by 19.4% in the fourth quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock valued at $139,000 after buying an additional 5,668 shares in the last quarter. Virtu Financial LLC bought a new position in Climb Bio in the fourth quarter valued at approximately $43,000. Blair William & Co. IL acquired a new position in shares of Climb Bio in the fourth quarter valued at approximately $44,000. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of Climb Bio by 11.9% in the third quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock valued at $268,000 after buying an additional 14,210 shares during the period. 69.76% of the stock is currently owned by institutional investors.

Climb Bio News Summary

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Raymond James initiated coverage with a “Strong Buy” recommendation, which likely attracted fresh demand from institutional investors. Raymond James initiates coverage
• Positive Sentiment: Market write‑ups report that an analyst upgrade helped push CLYM to a new 52‑week high, fueling momentum and higher trading volume. Sets New 52-Week High on Analyst Upgrade
• Neutral Sentiment: Reported short‑interest figures show zero shares (and NaN changes) with a days‑to‑cover of 0.0 — the data appears inconclusive or reporting‑anomalous and doesn’t provide a clear signal on crowd positioning.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly EPS estimates and lowered its FY2026 loss forecast (from about ($0.72) to ($1.08) per share), raising near‑term loss expectations. Those downward revisions can weigh on sentiment even though the firm kept a “Buy” rating. HC Wainwright Forecasts Strong Price Appreciation

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.